ADVANCED CELL TECHNOLOGY, INC. | 2013 | FY | 3


Summary of increases (decreases) in Net Loss for the years ended December 31, 2012 and 2011

 

    December 31,  
    2012     2011  
             
Net loss, as previously reported   $ (28,526,261 )   $ (72,795,119 )
Net adjustments                
Research and development     (3,124,100 )     199,465  
General and administrative expenses     (980,636 )     3,589,750  
Adjustments to fair value of unsettled warrant obligation     (1,953,118 )     13,813,101  
Net loss, restated   $ (34,584,115 )   $ (55,192,803 )
Basic loss per share:                
Net loss, as previously reported   $ (0.01 )   $ (0.05 )
Net adjustments                
Research and development     0.00       0.00  
General and administrative expenses     (0.01 )     0.00  
Adjustments to fair value of unsettled warrant obligation     (0.00 )     0.02  
Net loss, restated   $ (0.02 )   $ (0.03 )
Diluted loss per share:                
Net loss, as previously reported   $ (0.01 )   $ (0.05 )
Net adjustments                
Research and development     0.00       0.00  
General and administrative expenses     (0.01 )     0.00  
Adjustments to fair value of unsettled warrant obligation     (0.00 )     0.02  
Net loss, restated   $ (0.02 )   $ (0.03 )
Weighted average shares used in computing net loss per share:                
Basic     2,086,619,741       1,582,095,095  
Diluted     2,086,619,741       1,582,095,095  

 

Restatement adjustments on our Accumulated deficit as of January 1, 2011

 

    Amount  
         
Accumulated deficit, January 1, 2011, as previously reported   $ (180,949,523 )
Restatement adjustments:        
Adjustments to Additional Paid in Capital for tainted shares     1,064,499  
Adjustments to fair value of unsettled warrant obligation     (13,145,436 )
Accumulated deficit, January 1, 2011, as restated   $ (193,030,460 )

 

Consolidated Balance Sheet impact as of December 31, 2012

 

    As of December 31, 2012  
    As Previously Reported     Adjustments     As Restated  
Assets                        
Current assets:                        
Cash and cash equivalents   $ 7,241,852     $     $ 7,241,852  
Grants receivable     96,425             96,425  
Deferred royalty fees, current portion     82,435             82,435  
Prepaid expenses     132,044             132,044  
Total current assets     7,552,756             7,552,756  
Property and equipment, net     175,256             175,256  
Deferred royalty fees, less current portion     170,216             170,216  
Deposits     29,856             29,856  
Deferred costs, net     568,458             568,458  
Total assets   $ 8,496,542     $     $ 8,496,542  
Liabilities and Stockholders’ Deficit                        
Current liabilities:                        
Accounts payable   $ 2,956,743     $     $ 2,956,743  
Accrued expenses     3,210,908             3,210,908  
Accrued settlement     6,807,891             6,807,891  
Convertible promissory notes, current portion     256,850             256,850  
Senior secured convertible promissory notes, current portion     2,110,000             2,110,000  
Embedded conversion option liabilities, current portion     460,668             460,668  
Unsettled warrant obligation           3,791,953       3,791,953  
Loss contingency accrual     6,176,787       (2,506,500 )     3,670,287  
Deferred revenue, current portion     224,935             224,935  
Total current liabilities     22,204,782       1,285,453       23,490,235  
Senior secured convertible promissory notes, less current portion     3,165,000             3,165,000  
Embedded conversion option liabilities, less current portion     507,033             507,033  
Warrant and option derivative liabilities     972,381             972,381  
Deferred revenue, less current portion     1,907,574             1,907,574  
Total liabilities     28,756,770       1,285,453       30,042,223  
Series A-1 redeemable preferred stock     1,598,533             1,598,533  
Stockholders' Deficit:                        
Preferred stock, Series B     1             1  
Preferred stock, Series C     2             2  
Common stock     2,232,721             2,232,721  
Additional paid-in capital     289,842,597       (748,978 )     289,093,619  
Promissory notes receivable, net     (31,622,696 )           (31,622,696 )
Accumulated deficit     (282,311,386 )     (536,475 )     (282,847,861 )
Total stockholders' deficit     (21,858,761 )     (1,285,453 )     (23,144,214 )
Total liabilities and stockholders' deficit   $ 8,496,542     $     $ 8,496,542  

 

Consolidated Statement of Operations impact for the year ended December 31, 2012

 

    For the Year Ended December 31, 2012  
    As Previously Reported     Adjustments     As Restated  
                   
Revenue   $ 466,487     $     $ 466,487  
Cost of revenue     117,436             117,436  
Gross profit     349,051             349,051  
Operating expenses:                        
Research and development     11,034,836       3,124,100       14,158,936  
General and administrative expenses     10,452,230       980,636       11,432,866  
Total operating expenses     21,487,066       4,104,736       25,591,802  
Loss from operations     (21,138,015 )     (4,104,736 )     (25,242,751 )
Non-operating income (expense):                        
Interest income     15,581             15,581  
Interest expense and late fees     (1,104,602 )           (1,104,602 )
Finance gain (cost)     (3,671,970 )     (3,343,500 )     (7,015,470 )
Gain (loss) on disposal of fixed assets     (17,138 )           (17,138 )
Fines and penalties     (3,500,000 )           (3,500,000 )
Adjustments to fair value of unsettled warrant obligation           1,390,382       1,390,382  
Adjustments to fair value of derivatives     889,883             889,883  
Total non-operating expense     (7,388,246 )     (1,953,118 )     (9,341,364 )
Loss before provision for income tax     (28,526,261 )     (6,057,854 )     (34,584,115 )
Provision for income tax                  
Net loss   $ (28,526,261 )   $ (6,057,854 )   $ (34,584,115 )
Loss per share:                        
Basic   $ (0.01 )   $ (0.01 )   $ (0.02 )
Diluted     (0.01 )     (0.01 )     (0.02 )
Weighted average shares outstanding:                        
Basic     2,086,619,741       2,086,619,741       2,086,619,741  
Diluted     2,086,619,741       2,086,619,741       2,086,619,741  

 

Consolidated Statement of Operations impact for the year ended December 31, 2011

 

    For the Year Ended December 31, 2011  
    As Previously Reported     Adjustments     As Restated  
                   
Revenue   $ 506,419     $     $ 506,419  
Cost of revenue     343,950             343,950  
Gross profit     162,469             162,469  
Operating expenses:                        
Research and development     9,953,224       (199,465 )     9,753,759  
General and administrative expenses     11,025,459       (3,589,750 )     7,435,709  
Loss on settlement of litigation     294,144             294,144  
Total operating expenses     21,272,827       (3,789,215 )     17,483,612  
Loss from operations     (21,110,358 )     3,789,215       (17,321,143 )
Non-operating income (expense):                        
Interest income     35,114             35,114  
Interest expense and late fees     (1,510,693 )           (1,510,693 )
Finance gain (cost)     (60,834,170 )     5,850,000       (54,984,170 )
Loss attributable to equity method investments     (820,000 )           (820,000 )
Adjustments to fair value of unsettled warrant obligation           7,963,101       7,963,101  
Adjustments to fair value of derivatives     11,444,988             11,444,988  
Total non-operating expense     (51,684,761 )     13,813,101       (37,871,660 )
Loss before provision for income tax     (72,795,119 )     17,602,316       (55,192,803 )
Provision for income tax                  
Net loss   $ (72,795,119 )   $ 17,602,316     $ (55,192,803 )
Loss per share:                        
Basic   $ (0.05 )   $ 0.02     $ (0.03 )
Diluted     (0.05 )     0.02       (0.03 )
Weighted average shares outstanding:                        
Basic     1,582,095,095       1,582,095,095       1,582,095,095  
Diluted     1,582,095,095       1,582,095,095       1,582,095,095  

 

Consolidated Statement of Stockholders’ Deficit Impact

 

    For the Year Ended December 31,  
    2012     2011  
             
Stockholders’ deficit, as previously reported   $ (21,858,761 )   $ (46,123,844 )
Effect of restatement adjustment on net loss for the current period     (6,057,854 )     17,602,316  
Adjustment to additional paid-in capital for the current period     (748,978 )     (7,953,597 )
Cumulative adjustment to accumulated deficit     5,521,379       (12,080,937 )
Total restatement adjustments     (1,285,453 )     (2,432,218 )
Stockholders’ deficit, as restated   $ (23,144,214 )   $ (48,556,062 )

  

Consolidated Statement of Cash Flows Impact

 

    For the Year Ended December 31,  
    2012     2011  
    As Previously Reported     As Restated     As Previously Reported     As Restated  
                         
Net loss   $ (28,526,261 )   $ (34,584,115 )   $ (72,795,119 )   $ (55,192,803 )
Stock based compensation     3,691,149       7,795,885       3,856,501       67,286  
Adjustments to fair value of unsettled warrant obligation           (1,390,382 )           (7,963,101 )
Non-cash financing costs     3,671,970       7,015,470       60,834,170       54,984,170  
Net cash used in operating activities     (14,606,357 )

us-gaap:RestatementToPriorYearIncomeTextBlock